Transcode Therapeutics Inc.
05/14/2021 | Press release | Archived content
Correspondence (SEC Filing - CORRESP)
VIA EDGAR
May 14, 2021
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Jason Drory and Mary Beth Breslin
| Re: | TransCode Therapeutics, Inc. |
| Withdrawal of Acceleration Request | |
| Registration Statement on Form S-1 | |
| File No. 333-253599 |
Dear Mr. Drory and Ms. Breslin,
Reference is made to the letter of TransCode Therapeutics, Inc. (the 'Company'), filed as correspondence via EDGAR on May 6, 2021, in which the Company requested the acceleration of the effective time and date of Company's Registration Statement on Form S-1 (File No. 333-253599) (the 'Registration Statement') to 5:00 p.m., Eastern time, on May 10, 2021. The Company is no longer requesting that such Registration Statement be declared effective at this time and we hereby formally withdraw our request for acceleration of the effective date.
If you have any questions regarding this request, please contact Michael Bison of Goodwin Procter LLP at (617) 570-1933.
| Sincerely, | |
| TRANSCODE THERAPEUTICS, INC. | |
| /s/ Robert Michael Dudley | |
| Robert Michael Dudley | |
| Chief Executive Officer |
| cc: | Thomas A. Fitzgerald, TransCode Therapeutics, Inc. |
| Benjamin Bertan, Esq., Goodwin Procter LLP | |
| Kaitlin Carragher, Esq., Goodwin Procter LLP |